Ilepatril (AVE7688) is a potent, dual ACE-neutral endopeptidase (vasopeptidase) inhibitor with IC50 of 0.053 and 5.0 nM, respectively.
Ilepatril (AVE7688) displays good in vitro selectivity over a large variety of targets.
Ilepatril (AVE7688) restores endothelial function by increasing the ratio of NO to O2- concentration and bioavailability of NO, prevents albuminuria and reduces the incidence and severity of glomerulosclerosis and tubulointerstitial damage in vivo.
